Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland
Open Access
- 2 September 2014
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 111 (9) , 1824-1830
Abstract
In Scotland, a national HPV immunisation programme began in 2008 for 12- to 13-year olds, with a catch-up campaign from 2008 to 2011 for those under the age of 18. To monitor the impact of HPV immunisation on cervical disease at the population level, a programme of national surveillance was established. We analysed colposcopy data from a cohort of women born between 1988 and 1992 who entered the Scottish Cervical Screening Programme (SCSP) and were aged 20-21 in 2008-2012. By linking datasets from the SCSP and colposcopy services, we observed a significant reduction in diagnoses of cervical intraepithelial neoplasia 1 (CIN 1; RR 0.71, 95% CI 0.58 to 0.87; P=0.0008), CIN 2 (RR 0.5, 95% CI 0.4 to 0.63; P<0.0001) and CIN 3 (RR 0.45, 95% CI 0.35 to 0.58; P<0.0001) for women who received three doses of vaccine compared with unvaccinated women. To our knowledge, this is one of the first studies to show a reduction of low- and high-grade CIN associated with high uptake of the HPV bivalent vaccine at the population level. These data are very encouraging for countries that have achieved high HPV vaccine uptake.Keywords
This publication has 22 references indexed in Scilit:
- Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2012
- Using computerised decision support to improve compliance of cancer multidisciplinary meetings with evidence-based guidanceBMJ Open, 2012
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 VaccineJNCI: Journal of the National Cancer Institute, 2011
- Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological studyThe Lancet, 2011
- HPV type-specific prevalence using a urine assay in unvaccinated male and female 11- to 18-year olds in ScotlandBritish Journal of Cancer, 2011
- Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccinesBritish Journal of Cancer, 2010
- Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young womenThe Lancet, 2009
- Public awareness that HPV is a risk factor for cervical cancerBritish Journal of Cancer, 2007
- Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis updateInternational Journal of Cancer, 2007